ClinicalTrials.gg
TerminatedNCT04764474Updated Jan 29, 2026Results posted

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

A Phase 1 interventional study of HMPL-306 in Isocitrate Dehydrogenase Gene Mutation, sponsored by Hutchmed. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 200 studies in Leukemia, Myeloid, Acute with a site in Spain — 35 open to participants now, 62 under way, 22 of them phase 3. Leukemia, Myeloid, Acute · Spain.

Enrollment
148th of 189
46 · median 120
Started
2021
with 20 others
Phase 1
46 of 200
6 open now
Registered
141st of 200
by date

Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, this one is the 148th largest by enrollment of the 189 interventional ones that give a count, is one of 21 that started in 2021, is one of 46 in phase 1, and was the 141st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

35 of the 200 studies in Leukemia, Myeloid, Acute with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Leukemia, Myeloid, Acute with a site in Spain, or all of them as a file.
02

Study summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

Read the detailed description

HMPL-306 is a dual IDH1/2 inhibitor

This is a phase 1, open-label, multicenter, single-arm study to evaluate safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 administered orally in treatment of subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations (or co-mutations).

The study consists of 2 parts: a dose-escalation part (Part 1) and a dose-expansion part (Part 2). The dose-escalation part will determine the MTD/R2PD. The dose-expansion part will administer the MTD/RP2D to subjects with mIDH-positive AML

03

Conditions studied

  • Isocitrate Dehydrogenase Gene Mutation

Keywords

  • Acute Myeloid Leukemia
  • IDH Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Subjects may be enrolled in this study only if they satisfy all the following criteria (NOTE: This is not an exhaustive list):

  • Subjects aged ≥18 years.
  • performance status ≤ 2
  • Subjects with advanced , refractory, or resistant hematological , as defined below:

Part 1:

  • Subjects with documented IDH mutation per local or institutional next generation sequence (NGS).
  • Subjects must be refractory to or intolerant of established therapies.
  • Subjects who have received prior IDH inhibitor treatment may be enrolled in the escalation phase.

Part 2:

  • Subjects with documented IDH mutation of any of these subsets: IDH1 (R132C), IDH1 (R132H), IDH (R140Q), and IDH2 (R172K), including co-mutations and any combination thereof per local and institutional NGS.
  • Patients must have received at least 1 with an IDH inhibitor. An established standard of care with proven benefit for which the patient is eligible, must not be available at the time of enrollment.
  • Patients with AML must not have standard therapeutic options available (including IDH inhibitors where approved) and have the following:

    • i. Relapsed AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents;
    • ii. Primary refractory AML unsuitable for intensive chemotherapy or venetoclax-based regimen or target agents.
    • iii. Relapsed/refractory AML that has progressed on prior IDH treatment

Key Exclusion Criteria:

Subjects are not eligible for enrollment into this study if they meet any of the following criteria (NOTE: This is not an exhaustive list):

  • Subjects who received an agent \<14 days prior to their first day of study drug administration.
  • Subjects who are pregnant or breastfeeding.
  • Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever >38.3°C during screening visits or on their first day of study drug administration.
  • Subjects with some current or prior heart conditions.
  • Subjects taking medications that are known to prolong the may not be eligible.
  • Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
  • Some subjects with some current or prior gastrointestinal or liver diseases.
  • Subjects with inadequate organ function as defined by the protocol.
  • Subjects with a medical condition, physical examination finding, or clinical laboratory finding that, in the Investigators opinion, contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the subject at high risk from treatment complications.
  • Subjects with a known to HMPL-306 or to any of its .
  • Subjects with presence of second primary malignant tumors within the last 2 years, with the exception of the following, if medically controlled: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and carcinoma in situ of the breast.
  • Part 2 Only: The time since the last dose of prior IDH inhibitor treatment is within 30 days prior to the first day of study drug administration
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Treatment

    All patients will be administered HMPL-306 orally QD

    Drug: HMPL-306

Interventions

  • Administered orally QD in a 28-day continuous dosing treatment cycle

06

What researchers measure

Primary outcomes

  1. Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306

    RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, PK and pharmacodynamics (PD).

    Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

  2. Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)

    DLT was defined as occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study drug as per investigator's discretion: nonhematologic toxicity: TEAEs of Grade \>=4, Grade \>=3 with the exception of those that resolved within 72 hours (h) of onset; hematologic toxicity with the exception of neutropenia or thrombocytopenia that occurred with active leukemic disease: Grade 3 or 4 neutropenia lasting more than 7 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or any requirement for platelets (PLT) transfusion, Grade 3 or greater febrile neutropenia defined as absolute neutrophil count (ANC) 1000 per cubic millimeter with a single temperature of \>38.3 degree Celsius (°C) or a sustained temperature of \>=38°C for more than 1 h; any TEAE requiring a dose delay of \>=14 days or cases of confirmed Hy's law.

    Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

  3. Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)

    AE:unfavorable and unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed intervention, whether or not considered related to study drug. SAE:AE that resulted in death,life-threatening AE,inpatient hospitalization/prolongation of existing hospitalization,persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, abnormal pregnancy outcome in child born to female patient or female partner of male patient exposed to study drug or was important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration, or AE onset after 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.

    Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months

Secondary outcomes

  1. Number of Patients With Best Overall Response (BOR)

    BOR was defined as the best response during the anti-tumor evaluation period, which was determined using time point responses (TPRs) from date of the first dose of study drug from Cycle 1 in continuous cycle up until the last evaluable TPR prior to or on the date of PD/relapse according to the 2017 European LeukemiaNet criteria, or death; or withdrawal of consent or lost to follow-up; or receiving subsequent anti-cancer therapy, whichever was earlier. Number of patients with BOR \[complete response (CR), CR with negative minimal residual disease (CRmrd-), CR with partial hematological recovery (CRh), CR with incomplete count (CRi), morphologic leukemia-free state (MLFS), partial response (PR), stable disease (SD), and PD\] are reported.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS or PR. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  3. Time to Objective Response (TTOR)

    TTOR was defined as the time from the date of first study drug administration from Cycle 1 in continuous cycle to the date of first objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR). CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  4. Duration of Objective Response (DoOR)

    DoOR was defined as the time from the first occurrence of objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR) until PD, relapse, or death due to any cause, whichever came first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  5. Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS, PR, or SD lasting for 3 cycles. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%. SD: Not met criteria for CR, CRi, CRmrd-, MLFS, PR, or PD.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  6. Progression-Free Survival (PFS)

    PFS was defined as the time from the start of study drug from Cycle 1 in continuous cycle to PD, or relapse, or death due to any cause, whichever occurred first. PD was defined as increase in bone marrow blast percentage and/or absolute peripheral blood blast cells: a) myeloblasts percentage increased from baseline by \>50% (if blast cells at baseline were \<30%, net increased value needs to be \>=15%) or myeloblasts percentage \>70% continued for at least 3 months; ANC was not seen to be improved by at least 100%, reached (\>0.5x10\^9/L and/or PLT reached \>50x10\^9/L, without blood transfusion); b) the absolute peripheral blood blast cell count (WBCxblast cell ratio) increased by \>50% and reached \>25x10\^9/L (without differentiation syndrome); or new extramedullary diseases.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  7. Overall Survival (OS)

    OS was defined as the time from the start of study drug from Cycle 1 in continuous cycle until the date of death due to any cause.

    Time frame: From the first dose of study drug (Day 1) up to date of death due to any cause, approximately 45 months

  8. Event-Free Survival (EFS)

    EFS was defined as the time from date of first study drug administration from Cycle 1 in continuous cycle to treatment failure, relapse from CR (including CRmrd-, CR, CRh and CRi), or death due to any cause, whichever occurred first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. Treatment failure was defined as failure to achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24. Patients who did not achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24 were considered to have had an event at Day 1 of first study drug administration from Cycle 1 (excluding single oral dose from PK week). For remaining CR responders (including CRmrd-, CR, CRh and CRi), event time was time of either disease relapse or death due to any cause, whichever occurred first.

    Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months

  9. Number of Patients With Post-Baseline Transfusion Independence (TI)

    Post-baseline TI was defined as the absence of red blood cell and platelet transfusions for a pre-specified time during treatment period which was defined from the first dose of study drug administration from Cycle 1 in continuous cycle to 30 days after the last dose date or prior to the start of a subsequent anti-tumor therapy (whichever came first). Number of patients with post-baseline TI for \>=4 weeks and \>=8 weeks is presented.

    Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months

  10. Plasma Concentrations of HMPL-306

    Blood samples were collected at the specified timepoints to determine plasma concentrations of HMPL-306.

    Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1

  11. Maximum Observed Plasma Concentration (Cmax) of HMPL-306

    Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.

    Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1

  12. Time to Reach the Maximum Plasma Concentration (Tmax) of HMPL-306

    Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.

    Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1

  13. Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306

    Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.

    Time frame: PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1

  14. Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)

    Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate for patients in different dose groups are presented.

    Time frame: From PK Week Day 2 until end of treatment, approximately 24.25 months

07

Results

Posted Jan 29, 2026
Limitations and caveats
The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns.

Participant flow

This Phase 1, 2-part, open-label study was conducted in patients with advanced relapsed/refractory or resistant hematological malignancies that harbor isocitrate dehydrogenase mutations. The study consisted of dose escalation part (Part 1) and dose expansion part (Part 2). A total of 46 patients were enrolled in this study.

Participant flow — Overall Study
MilestoneCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Started331176448
Completed00000000
Not completed331176448
Withdrew: Death13755324
Withdrew: Sponsor terminated study00411013
Withdrew: Withdrawal of consent20000111
Withdrew: Other00010000

Outcome measures

PrimaryDose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306

RP2D determination took the following criteria under consideration: determination of maximum tolerated dose (MTD) achieved during the dose escalation part and assessment of safety, PK and pharmacodynamics (PD).

Time frame:
From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Reported as:
Number · mg
Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306
mgDose Escalation Part: Cohorts 1 to 8: HMPL-306
Dose Escalation Part: Recommended Phase 2 Dose (RP2D) of HMPL-306NA
PrimaryDose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)

DLT was defined as occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study drug as per investigator's discretion: nonhematologic toxicity: TEAEs of Grade \>=4, Grade \>=3 with the exception of those that resolved within 72 hours (h) of onset; hematologic toxicity with the exception of neutropenia or thrombocytopenia that occurred with active leukemic disease: Grade 3 or 4 neutropenia lasting more than 7 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or any requirement for platelets (PLT) transfusion, Grade 3 or greater febrile neutropenia defined as absolute neutrophil count (ANC) 1000 per cubic millimeter with a single temperature of \>38.3 degree Celsius (°C) or a sustained temperature of \>=38°C for more than 1 h; any TEAE requiring a dose delay of \>=14 days or cases of confirmed Hy's law.

Time frame:
From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
Reported as:
Count of participants · Participants
Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)
ParticipantsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Dose Escalation Part: Number of Patients With Dose-Limiting Toxicities (DLTs)00000000
PrimaryNumber of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)

AE:unfavorable and unintended sign,symptom or disease temporally associated with use of study drug or other protocol-imposed intervention, whether or not considered related to study drug. SAE:AE that resulted in death,life-threatening AE,inpatient hospitalization/prolongation of existing hospitalization,persistent/significant incapacity or substantial disruption of ability to conduct normal life functions, abnormal pregnancy outcome in child born to female patient or female partner of male patient exposed to study drug or was important medical event that jeopardized patient and required medical/surgical intervention to prevent above outcome. TEAE:AE with onset on/after start of study drug until 30 days after last dose or prior to start of subsequent anti-tumor therapy, or AE with onset before start of study drug but worsened in severity after study drug administration, or AE onset after 30 days after last dose or after start of subsequent anti-tumor therapy and treatment-related SAEs.

Time frame:
From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months
Reported as:
Count of participants · Participants
Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Any TEAE331176348
Any TESAE31655345
SecondaryNumber of Patients With Best Overall Response (BOR)

BOR was defined as the best response during the anti-tumor evaluation period, which was determined using time point responses (TPRs) from date of the first dose of study drug from Cycle 1 in continuous cycle up until the last evaluable TPR prior to or on the date of PD/relapse according to the 2017 European LeukemiaNet criteria, or death; or withdrawal of consent or lost to follow-up; or receiving subsequent anti-cancer therapy, whichever was earlier. Number of patients with BOR \[complete response (CR), CR with negative minimal residual disease (CRmrd-), CR with partial hematological recovery (CRh), CR with incomplete count (CRi), morphologic leukemia-free state (MLFS), partial response (PR), stable disease (SD), and PD\] are reported.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Count of participants · Participants
Number of Patients With Best Overall Response (BOR)
ParticipantsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
CRmrd-00010001
CR00300013
CRh00011010
CRi00202001
MLFS00000000
PR00000000
SD10100100
PD01322212
Not evaluable22110101
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS or PR. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Number · percentage of patients
Objective Response Rate (ORR)
percentage of patientsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Objective Response Rate (ORR)0 (NA to NA)0 (NA to NA)50.0 (18.7 to 81.3)40.0 (5.3 to 85.3)60.0 (14.7 to 94.7)0 (NA to NA)66.7 (9.4 to 99.2)62.5 (24.5 to 91.5)
SecondaryTime to Objective Response (TTOR)

TTOR was defined as the time from the date of first study drug administration from Cycle 1 in continuous cycle to the date of first objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR). CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Median · months
Time to Objective Response (TTOR)
monthsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Time to Objective Response (TTOR)——3.680 (3.09 to 5.45)2.316 (0.95 to 3.68)4.600 (1.77 to 4.90)—2.891 (2.07 to 3.71)1.87 (1.84 to 1.87)
SecondaryDuration of Objective Response (DoOR)

DoOR was defined as the time from the first occurrence of objective response (CRmrd-, CR, CRh, CRi, MLFS, or PR) until PD, relapse, or death due to any cause, whichever came first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Median · months
Duration of Objective Response (DoOR)
monthsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Duration of Objective Response (DoOR)——5.19 (1.87 to NA)15.28 (7.43 to NA)0.84 (0.69 to NA)—1.87 (NA to NA)3.71 (1.87 to NA)
SecondaryClinical Benefit Rate (CBR)

CBR was defined as the percentage of patients with BOR being CRmrd-, CR, CRh, CRi, MLFS, PR, or SD lasting for 3 cycles. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. MLFS: myeloblast \<5%, blast cells without Auer bodies, no extramedullary lesion, no hematological recovery requirements. PR: met all hematological criteria for CR, percentage of myeloblasts decreased from baseline by least 50% and reached 5% to 25%. SD: Not met criteria for CR, CRi, CRmrd-, MLFS, PR, or PD.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Number · percentage of patients
Clinical Benefit Rate (CBR)
percentage of patientsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Clinical Benefit Rate (CBR)33.3 (0.8 to 90.6)0 (NA to NA)60.0 (26.2 to 87.8)40.0 (5.3 to 85.3)60.0 (14.7 to 94.7)25.0 (0.6 to 80.6)66.7 (9.4 to 99.2)62.5 (24.5 to 91.5)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the start of study drug from Cycle 1 in continuous cycle to PD, or relapse, or death due to any cause, whichever occurred first. PD was defined as increase in bone marrow blast percentage and/or absolute peripheral blood blast cells: a) myeloblasts percentage increased from baseline by \>50% (if blast cells at baseline were \<30%, net increased value needs to be \>=15%) or myeloblasts percentage \>70% continued for at least 3 months; ANC was not seen to be improved by at least 100%, reached (\>0.5x10\^9/L and/or PLT reached \>50x10\^9/L, without blood transfusion); b) the absolute peripheral blood blast cell count (WBCxblast cell ratio) increased by \>50% and reached \>25x10\^9/L (without differentiation syndrome); or new extramedullary diseases.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Progression-Free Survival (PFS)6.80 (NA to NA)3.42 (1.87 to NA)5.08 (0.62 to NA)7.39 (3.22 to NA)4.57 (2.10 to NA)3.71 (1.87 to NA)5.55 (0.79 to NA)4.62 (0.49 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the start of study drug from Cycle 1 in continuous cycle until the date of death due to any cause.

Time frame:
From the first dose of study drug (Day 1) up to date of death due to any cause, approximately 45 months
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Overall Survival (OS)6.80 (NA to NA)4.57 (3.42 to NA)13.01 (0.62 to NA)15.24 (5.19 to NA)7.66 (5.36 to NA)9.89 (3.06 to NA)6.01 (0.79 to NA)13.47 (0.49 to NA)
SecondaryEvent-Free Survival (EFS)

EFS was defined as the time from date of first study drug administration from Cycle 1 in continuous cycle to treatment failure, relapse from CR (including CRmrd-, CR, CRh and CRi), or death due to any cause, whichever occurred first. CR: myeloblast \<5%, blast cells without Auer bodies, no blast cells in peripheral blood, no extramedullary lesion, ANC \>=1.0x10\^9/L, PLT \>=100x10\^9/L. CRmrd-: CR with negative RT-qPCR or CR with negative MFC. CRi: met all other criteria of CR but ANC \<1.0x10\^9/L or PLT \<100x10\^9/L. Treatment failure was defined as failure to achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24. Patients who did not achieve CR (including CRmrd-, CR, CRh, CRi) by Week 24 were considered to have had an event at Day 1 of first study drug administration from Cycle 1 (excluding single oral dose from PK week). For remaining CR responders (including CRmrd-, CR, CRh and CRi), event time was time of either disease relapse or death due to any cause, whichever occurred first.

Time frame:
Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-14 days) thereafter until end of treatment, or end of efficacy follow-up period, approximately 45 months
Reported as:
Median · months
Event-Free Survival (EFS)
monthsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Event-Free Survival (EFS)0.03 (NA to NA)0.03 (NA to NA)0.03 (0.03 to 5.65)0.03 (0.03 to NA)5.55 (0.03 to NA)0.03 (NA to NA)5.55 (0.03 to NA)4.62 (0.03 to NA)
SecondaryNumber of Patients With Post-Baseline Transfusion Independence (TI)

Post-baseline TI was defined as the absence of red blood cell and platelet transfusions for a pre-specified time during treatment period which was defined from the first dose of study drug administration from Cycle 1 in continuous cycle to 30 days after the last dose date or prior to the start of a subsequent anti-tumor therapy (whichever came first). Number of patients with post-baseline TI for \>=4 weeks and \>=8 weeks is presented.

Time frame:
From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 25.25 months
Reported as:
Count of participants · Participants
Number of Patients With Post-Baseline Transfusion Independence (TI)
ParticipantsCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Post-baseline TI for >=4 weeks33744438
Post-baseline TI for >=8 weeks00624126
SecondaryPlasma Concentrations of HMPL-306

Blood samples were collected at the specified timepoints to determine plasma concentrations of HMPL-306.

Time frame:
PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Reported as:
Mean · nanogram per milliliter (ng/mL)
Plasma Concentrations of HMPL-306
nanogram per milliliter (ng/mL)Cohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
PK Week: Pre-dose on Day 1NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
PK Week: 0.5 hour post-dose on Day 140.6 ± 33.112.8 ± 9.02155 ± 20040.5 ± 66.0101 ± 59.628.5 ± 41.965.0 ± 80.9206 ± 266
PK Week: 1 hour post-dose on Day 1115 ± 67.5223 ± 161320 ± 256249 ± 278541 ± 292268 ± 285258 ± 171826 ± 545
PK Week: 2 hours post-dose on Day 1151 ± 80.5412 ± 260417 ± 140535 ± 254955 ± 772999 ± 112777 ± 559869 ± 524
PK Week: 3 hours post-dose on Day 1130 ± 39.5275 ± 103379 ± 109498 ± 209868 ± 853970 ± 229689 ± 241918 ± 539
PK Week: 4 hours post-dose on Day 193.9 ± 8.70164 ± 64.8293 ± 126379 ± 114596 ± 525744 ± 316601 ± 220985 ± 703
PK Week: 6 hours post-dose on Day 148.9 ± 20.6131 ± 26.5192 ± 76.5248 ± 71.5327 ± 164387 ± 85.8498 ± 227719 ± 529
PK Week: 8 hours post-dose on Day 147.3 ± 21.2110 ± 32.6151 ± 45.6204 ± 72.5249 ± 191331 ± 73.7375 ± 111517 ± 257
PK Week: 24 hours post-dose on Day 123.8 ± 2.1563.5 ± 27.085.6 ± 20.6113 ± 21.9167 ± 76.8177 ± 55.6183 ± 56.6301 ± 148
PK Week: 48 hours post-dose on Day 117.1 ± 1.0042.9 ± 23.764.3 ± 14.279.2 ± 18.4119 ± 49.7119 ± 22.9132 ± 51.9202 ± 106
PK Week: 72 hours post-dose on Day 115.9 ± 3.2939.9 ± 15.855.9 ± 16.166.3 ± 12.897.1 ± 48.1108 ± 19.9114 ± 48.4167 ± 76.1
PK Week: 96 hours post-dose on Day 113.4 ± 1.0234.2 ± 14.952.5 ± 15.061.2 ± 11.783.8 ± 38.893.0 ± 15.388.0 ± 48.8175 ± 84.6
PK Week: 120 hours post-dose on Day 113.3 ± 1.5632.2 ± 14.643.0 ± 13.252.9 ± 4.7364.0 ± 25.979.8 ± 13.183.3 ± 38.9138 ± 73.4
PK Week: 144 hours post-dose on Day 111.7 ± 0.42429.4 ± 12.940.5 ± 14.047.2 ± 4.1856.2 ± 28.172.2 ± 3.6855.8 ± 26.2132 ± 71.8
PK Week: 168 hours post-dose on Day 19.62 ± 0.67927.6 ± 20.938.9 ± 14.846.2 ± 8.6490.3 ± 24.964.6 ± 8.6250.7 ± 22.7125 ± 68.4
Cycle 2 Day 1: Pre-dose134 ± NA501 ± 244765 ± 359765 ± 110916 ± 5731558 ± 6371475 ± 2472133 ± 978
Cycle 2 Day 1: 0.5 h post-dose134 ± NA592 ± 404921 ± 458871 ± 3001622 ± 15101632 ± 7001585 ± 3182616 ± 972
Cycle 2 Day 1: 1 h post-dose218 ± NA666 ± 4861324 ± 6111063 ± 3191930 ± 12732167 ± 9812250 ± 1702776 ± 1066
Cycle 2 Day 1: 2 h post-dose293 ± NA755 ± 2671191 ± 5011208 ± 3631910 ± 10752310 ± 9192250 ± 5943372 ± 948
Cycle 2 Day 1: 3 h post-dose282 ± NA738 ± 1071084 ± 5511227 ± 2391730 ± 8912213 ± 4191630 ± NA2887 ± 1194
Cycle 2 Day 1: 4 h post-dose253 ± 89.1573 ± 26.9999 ± 351946 ± 1251180 ± 6081873 ± 5971695 ± 5302345 ± 775
Cycle 2 Day 1: 6 h post-dose252 ± 114505 ± 96.9851 ± 298870 ± 1251082 ± 4931697 ± 4311445 ± 4032242 ± 910
Cycle 2 Day 1: 8 h post-dose276 ± 148592 ± 164813 ± 397829 ± 27.0970 ± 5231770 ± 5021640 ± 6362170 ± 972
Cycle 2 Day 1: 24 h post-dose206 ± 96.2502 ± 160837 ± 317746 ± 96.8899 ± 5531484 ± 4881230 ± NA2135 ± 1063
SecondaryMaximum Observed Plasma Concentration (Cmax) of HMPL-306

Blood samples were collected at the specified timepoints to determine Cmax of HMPL-306.

Time frame:
PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of HMPL-306
ng/mLCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
PK Week Day 1151 ± 33.7376 ± 71.8476 ± 36.6574 ± 44.2749 ± 76.51095 ± 13.4865 ± 53.51225 ± 45.0
Cycle 2 Day 1413 ± 51.7921 ± 30.21239 ± 61.61365 ± 21.61804 ± 70.72455 ± 31.12385 ± 16.13301 ± 31.5
SecondaryTime to Reach the Maximum Plasma Concentration (Tmax) of HMPL-306

Blood samples were collected at the specified timepoints to determine Tmax of HMPL-306.

Time frame:
PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Reported as:
Median · hour
Time to Reach the Maximum Plasma Concentration (Tmax) of HMPL-306
hourCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
PK Week Day 11.98 (0.950 to 2.92)1.93 (1.83 to 3.00)1.98 (0.933 to 3.00)1.92 (1.02 to 3.00)2.00 (1.00 to 3.00)3.00 (2.23 to 4.00)3.06 (2.10 to 6.00)2.09 (1.00 to 6.05)
Cycle 2 Day 12.38 (2.10 to 2.67)2.43 (1.03 to 2.98)1.00 (1.00 to 4.00)2.50 (2.00 to 3.00)1.50 (1.00 to 2.00)2.00 (1.03 to 3.00)1.51 (1.00 to 2.02)2.00 (1.92 to 2.87)
SecondaryArea Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306

Blood samples were collected at the specified timepoints to determine AUC0-24 of HMPL-306.

Time frame:
PK Week: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 PK week; Cycle 2 Day 1: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 24 hours post-dose on Cycle 2 Day 1
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of HMPL-306
h*ng/mLCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
PK Week Day 11143 ± 34.82625 ± 42.73780 ± 23.84811 ± 22.16436 ± 58.08368 ± 16.47846 ± 36.311211 ± 47.1
Cycle 2 Day 15697 ± 52.312904 ± 24.019159 ± 53.620313 ± 8.523740 ± 66.939882 ± 34.637973 ± 30.150156 ± 43.2
SecondaryMaximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)

Blood samples were collected at the specified timepoints to determine plasma concentrations of 2-HG which was a PD marker. The maximum inhibition rate for patients in different dose groups are presented.

Time frame:
From PK Week Day 2 until end of treatment, approximately 24.25 months
Reported as:
Mean · percentage of inhibition
Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)
percentage of inhibitionCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)65.85 ± 24.7071.49 ± 33.0761.23 ± 33.6782.67 ± 14.2159.51 ± 61.6288.54 ± 11.1194.28 ± 4.8287.47 ± 13.23

Adverse events

Collected over Adverse events were collected from the first dose of study drug (Day 1 of the PK week) up to 30 days after the last dose of study drug, or prior to the start of a subsequent anti-tumor therapy (whichever came first), approximately 25.25 months. All-cause mortality (deaths) were collected from the first dose of study drug (Day 1 of the PK week) up to end of follow-up, approximately 45 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: HMPL-306 Dose Level 11/3 (33.3%)3/3 (100%)3/3 (100%)
Cohort 2: HMPL-306 Dose Level 23/3 (100%)1/3 (33.3%)3/3 (100%)
Cohort 3: HMPL-306 Dose Level 37/11 (63.6%)6/11 (54.5%)10/11 (90.9%)
Cohort 4: HMPL-306 Dose Level 45/7 (71.4%)5/7 (71.4%)7/7 (100%)
Cohort 5: HMPL-306 Dose Level 55/6 (83.3%)5/6 (83.3%)6/6 (100%)
Cohort 6: HMPL-306 Dose Level 63/4 (75%)3/4 (75%)3/4 (75%)
Cohort 7: HMPL-306 Dose Level 72/4 (50%)4/4 (100%)3/4 (75%)
Cohort 8: HMPL-306 Dose Level 84/8 (50%)5/8 (62.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
PneumoniaInfections and infestations1/31/33/111/72/60/42/41/8
SepsisInfections and infestations0/31/31/111/71/62/40/40/8
Septic shockInfections and infestations1/31/30/110/70/60/40/40/8
CellulitisInfections and infestations0/31/30/110/70/60/40/40/8
Escherichia bacteraemiaInfections and infestations0/31/30/110/70/60/40/40/8
Perirectal abscessInfections and infestations0/31/30/110/70/60/40/40/8
Pneumonia fungalInfections and infestations1/30/30/110/70/60/40/40/8
Febrile neutropeniaBlood and lymphatic system disorders0/30/31/112/72/60/41/41/8
LeukocytosisBlood and lymphatic system disorders0/31/30/110/70/60/40/40/8
VomitingGastrointestinal disorders1/30/30/110/70/60/40/40/8
Most frequent other events
Showing 10 of 159
Most frequent other events
EventCohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8
AnaemiaBlood and lymphatic system disorders0/33/31/111/72/61/41/43/8
FatigueGeneral disorders3/31/31/110/70/60/40/40/8
Febrile neutropeniaBlood and lymphatic system disorders2/31/30/111/71/60/40/40/8
Increased tendency to bruiseBlood and lymphatic system disorders2/30/30/110/70/60/40/40/8
Oedema peripheralGeneral disorders1/32/31/111/70/60/40/40/8
Alanine aminotransferase increasedInvestigations2/30/31/111/72/61/40/40/8
Aspartate aminotransferase increasedInvestigations2/30/31/110/72/61/40/40/8
Decreased appetiteMetabolism and nutrition disorders2/31/31/111/70/60/40/41/8
EpistaxisRespiratory, thoracic and mediastinal disorders2/31/31/112/70/60/40/40/8
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/32/30/110/71/60/40/40/8

Baseline characteristics

The safety analysis set included all enrolled patients who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8Total
Mean65.7 ± 5.6965.0 ± 10.1572.3 ± 6.9268.7 ± 5.6869.2 ± 12.0466.5 ± 17.7167.3 ± 10.9070.4 ± 13.4669.2 ± 9.98
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8Total
Female2162312421
Male1255332425
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8Total
Hispanic or Latino0215110313
Not Hispanic or Latino3182534531
Unknown or Not Reported002000002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: HMPL-306 Dose Level 1Cohort 2: HMPL-306 Dose Level 2Cohort 3: HMPL-306 Dose Level 3Cohort 4: HMPL-306 Dose Level 4Cohort 5: HMPL-306 Dose Level 5Cohort 6: HMPL-306 Dose Level 6Cohort 7: HMPL-306 Dose Level 7Cohort 8: HMPL-306 Dose Level 8Total
Asian000010012
White3287544740
Unknown or Not Reported013000004
08

Study locations

15 sites
  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • Winship Cancer Institute - Emory University
    Atlanta, Georgia 30322, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Froedtert-Medical College of WI
    Milwaukee, Wisconsin 53226, United States
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, Valencia 46010, Spain
  • Hospital Universitario La Fe
    Valencia, Valencia 46026, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • START Madrid - Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 58-182, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jan 2025, 45 months.

Results were first posted in Jan 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2021
First posted
Feb 21, 2021
StartActual
Apr 12, 2021
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 15, 2025
Results first posted
Jan 29, 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04764474
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Apr 12, 2021
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025
Results posted
Jan 29, 2026
Last update
Jan 29, 2026

Study contacts

Bo Zhang
study director · Hutchison Medipharma Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranosidenib

Start the discussion